# Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation

Study · id `cardio:ct-nct02145546` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02145546](<https://clinicaltrials.gov/study/NCT02145546>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02145546

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

## Technical summary

Registry record NCT02145546. Randomized; no masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2017-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT02145546, source copy `cardio:ctgov-nct02145546-2014-05-23`, retrieved 2026-10-26)
- Start date: 2014-05 (registry gives no type) (ClinicalTrials.gov record NCT02145546, source copy `cardio:ctgov-nct02145546-2014-05-23`, retrieved 2026-10-26)
- Primary completion: 2017-05 (anticipated) (ClinicalTrials.gov record NCT02145546, source copy `cardio:ctgov-nct02145546-2014-05-23`, retrieved 2026-10-26)
- Completion: 2017-05 (anticipated) (ClinicalTrials.gov record NCT02145546, source copy `cardio:ctgov-nct02145546-2014-05-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02145546, source copy `cardio:ctgov-nct02145546-2014-05-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02145546-2014-05-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation
- Acronym: ADA-PAF
- Condition: Atrial Fibrillation
- Intervention (Drug): Amiodarone
- Intervention (Drug): Propafenone
- Intervention (Drug): Sotalol
- Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER
- Collaborator: Medtronic (Shanghai) Management Co. Ltd.
- Collaborator class: INDUSTRY
- Collaborator: Beijing CTSmed Co. Ltd
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Amiodarone (`cardio:amiodarone`)
- Registry lists this organization as the lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (`cardio:org-xinhua-hospital-shanghai-jiao-tong-university-school-of-9039af`)

## Provenance

Content hash: f7cd351a00b473fd1e3eadf3da9840cd482ca4980103c420f0995d4c514c9f93
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
